Heartflow (NASDAQ:HTFL) CFO Vikram Verghese Sells 5,876 Shares

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 5,876 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $50.60, for a total transaction of $297,325.60. Following the completion of the sale, the chief financial officer owned 248,683 shares in the company, valued at approximately $12,583,359.80. This trade represents a 2.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total value of $1,368,462.60.

Heartflow Stock Down 1.6%

Shares of Heartflow stock opened at $48.91 on Friday. The business has a 50-day moving average price of $33.76 and a 200 day moving average price of $29.92. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $51.78. The firm has a market cap of $4.25 billion and a P/E ratio of -26.73.

Heartflow (NASDAQ:HTFL) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The company’s revenue for the quarter was up 47.7% on a year-over-year basis. As a group, equities research analysts anticipate that Heartflow, Inc. will post -0.75 earnings per share for the current year.

Institutional Trading of Heartflow

Hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new position in Heartflow in the 4th quarter worth about $27,000. Russell Investments Group Ltd. acquired a new stake in shares of Heartflow during the 4th quarter valued at $45,000. Essential Partners LLC acquired a new position in shares of Heartflow in the 1st quarter worth $57,000. Legal & General Group Plc acquired a new stake in Heartflow during the 3rd quarter worth about $59,000. Finally, Strs Ohio purchased a new stake in shares of Heartflow in the 4th quarter valued at approximately $99,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on HTFL shares. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Morgan Stanley increased their price objective on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Canaccord Genuity Group lifted their target price on Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Robert W. Baird set a $45.00 target price on Heartflow in a report on Friday, August 14th. Finally, Wells Fargo & Company raised their price target on Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.43.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.